Study guide
7.2 Meconium Aspiration Syndrome (MAS) & Persistent Pulmonary Hypertension (PPHN)
Neonatal Pediatric Transport C-NPT
Track your progress as you read
Finished sections get a check mark.
1 Introduction: The C-NPT Exam
About the C-NPT Exam: 2026 Format, Eligibility & Content Outline
2 Chapter 1: Transport Systems, Regulatory Framework & Legal Issues
1.1 Transport System Architecture, Accreditation (CAMTS) & Dispatch Triage 1.2 Regulatory & Legal Mandates: EMTALA, HIPAA, Consent & Documentation 1.3 Medical Direction, Scope of Practice & Ethical Considerations
3 Chapter 2: Safety, Communication, Crew Resource Management & Transport Environment
2.1 Crew Resource Management (CRM), Situational Awareness & Sterile Cockpit 2.2 Aircraft & Ground Ambulance Operations, Landing Zones & Vehicle Dynamics 2.3 Environmental Hazards, Weather Minimums & In-Flight Emergency Procedures 2.4 Communication in Transport: Peer Handoffs, Age-Appropriate Care, Families & Crew Stressors 2.5 Infection Control, PPE, Scene Safety & Disaster/Evacuation Planning
4 Chapter 3: Flight Physiology & Environmental Stressors
3.1 Physical Gas Laws & Transport Implications (Boyle, Dalton, Charles, Henry, Graham) 3.2 Altitude Hypoxia, Barometric Pressure Changes & Dysbarism 3.3 Acceleration Forces (G-forces), Vibration & Acoustic Stress in Transit 3.4 Thermoregulation Physics & Neutral Thermal Environment in Transit
5 Chapter 4: Invasive Procedures & Transport Monitoring
4.1 Advanced Airway Management & Endotracheal Intubation in Transit 4.2 Pleural Decompression (Needle Thoracostomy & Chest Tube Management) 4.3 Vascular Access: Umbilical Lines (UAC/UVC), Intraosseous (IO) & Arterial Lines
6 Chapter 5: Transport Equipment, Respiratory Physiology & Mechanical Ventilation
5.1 Transport Incubators (Isolettes), Thermal Control & Electrical/Gas Power Systems 5.2 Portable Ventilators & Modes (PC, VC, PRVC, High Frequency) 5.3 Gas Cylinder Duration Calculations, Oxygen Delivery & Inhaled Nitric Oxide (iNO) 5.4 Respiratory Physiology: Acid-Base Balance, Oxygenation, Lung Mechanics & Troubleshooting
7 Chapter 6: Transport Pharmacology, Resuscitation, Fluids & Electrolytes
6.1 Vasoactive Infusions & Inotropes (Epinephrine, Dopamine, Dobutamine, Milrinone) 6.2 Sedation, Analgesia & Neuromuscular Blockade in Transport 6.3 Prostaglandin E1 (Alprostadil) & Surfactant Replacement Therapy 6.4 Resuscitation Protocols (NRP, PALS) & Shock Fluid Resuscitation 6.5 Antimicrobial Pharmacology in Neonatal & Pediatric Transport 6.6 Post-Resuscitation Care, Defibrillation & Cardioversion in Transit, ECMO Indications & the Transport-vs-Stay Decision 6.7 Fluid & Electrolyte Therapy Across the Ages: Maintenance, Dehydration, Fluid Overload & Electrolyte Emergencies
8 Chapter 7: Neonatal Respiratory Pathologies & Management
7.1 Respiratory Distress Syndrome (RDS) & Surfactant Deficiency 7.2 Meconium Aspiration Syndrome (MAS) & Persistent Pulmonary Hypertension (PPHN) 7.3 Transient Tachypnea (TTN), Neonatal Pneumothorax & Congenital Diaphragmatic Hernia (CDH) 7.4 Neonatal Upper Airway Anomalies, Aspiration, Pneumonia, Chronic Lung Disease & Respiratory Failure
9 Chapter 8: Neonatal Cardiovascular Critical Care
8.1 Ductal-Dependent Cyanotic Congenital Heart Defects (TGA, TOF, Tricuspid Atresia) 8.2 Ductal-Dependent Systemic Blood Flow Lesions (HLHS, Coarctation, Interrupted Arch) 8.3 Neonatal Arrhythmias, Cardiogenic Shock & Post-Resuscitation Care 8.4 Acyanotic Congenital Heart Lesions, Patent Ductus Arteriosus, Obstructed TAPVR & Neonatal Heart Failure
10 Chapter 9: Neonatal Neurological & Metabolic Crises
9.1 Hypoxic-Ischemic Encephalopathy (HIE) & Passive/Active Therapeutic Hypothermia 9.2 Neonatal Seizures & Intraventricular Hemorrhage (IVH) 9.3 Neonatal Hypoglycemia, Electrolyte Derangements & Hyperbilirubinemia 9.4 Subgaleal Hemorrhage, Neonatal Sepsis & Meningitis, and Perinatal Substance Exposure (NOWS)
11 Chapter 10: Neonatal Surgical Emergencies, Neural Tube Defects & ELBW Care
10.1 Abdominal Wall Defects (Gastroschisis vs. Omphalocele) & TEF/Esophageal Atresia 10.2 Necrotizing Enterocolitis (NEC), Malrotation with Volvulus & Intestinal Obstruction 10.3 Care of the Extremely Low Birth Weight (ELBW) Infant (<1000g) in Transit 10.4 Neural Tube Defects: Myelomeningocele, Encephalocele & Transport of the Newborn With an Open Spinal Defect
12 Chapter 11: Pediatric Respiratory Emergencies
11.1 Acute Upper Airway Obstruction (Croup, Epiglottitis, Bacterial Tracheitis, Foreign Body) 11.2 Lower Airway Crises: Status Asthmaticus & Severe Bronchiolitis 11.3 Pediatric Acute Respiratory Distress Syndrome (PARDS) & Severe Pneumonia
13 Chapter 12: Pediatric Shock & Cardiovascular Crises
12.1 Pathophysiology & Transport Management of Pediatric Septic Shock 12.2 Hypovolemic, Cardiogenic & Anaphylactic Shock in Children 12.3 Pediatric Cardiac Emergencies: SVT, Ventricular Arrhythmias & Myocarditis 12.4 Pediatric Cardiovascular Crises: Palliated Congenital Heart Disease, Pulmonary Hypertensive Crisis, Pericarditis & Tamponade, Hypertensive Emergency & Anterior Mediastinal Mass
14 Chapter 13: Pediatric Neurological Emergencies & Trauma
13.1 Status Epilepticus, Altered Mental Status & Meningitis/Encephalitis 13.2 Pediatric Traumatic Brain Injury (TBI) & Increased Intracranial Pressure (ICP) 13.3 Blunt/Penetrating Trauma, Spinal Motion Restriction & Thermal Burns 13.4 Non-Accidental Trauma, Smoke Inhalation (Carbon Monoxide & Cyanide) & Heat Illness
15 Chapter 14: Pediatric Toxicological, Environmental & Endocrine Emergencies
14.1 Common Pediatric Toxic Ingestions, Poisonings & Antidotes 14.2 Diabetic Ketoacidosis (DKA) & Environmental Emergencies (Submersion, Hypothermia) 14.3 Button Battery & Foreign-Body Ingestions, Bites & Envenomations, and Hazardous-Material Exposures
16 Chapter 15: Pediatric Metabolic & Hematologic Emergencies
15.1 Anemia, Sickle Cell Disease, Coagulopathies & Blood Product Administration 15.2 Oncologic Emergencies, Acute Kidney Injury & Pediatric Electrolyte Crises
7.2 Meconium Aspiration Syndrome (MAS) & Persistent Pulmonary Hypertension (PPHN)
Key Takeaways Explain This Topic AI
Meconium aspiration creates a triad of mechanical airway obstruction, chemical pneumonitis, and secondary surfactant inactivation, generating high risks for dynamic air trapping, tension pneumothoraces, and secondary PPHN.
Current neonatal resuscitation guidelines strictly prohibit routine endotracheal intubation and suctioning for both vigorous and non-vigorous meconium-stained infants; initial management prioritizes immediate warming, drying, stimulation, and bag-mask ventilation if apneic or bradycardic.
Ventilator management in severe MAS demands prolonged expiratory times (I:E ratio 1:2 to 1:3, rates 30-40 bpm) to prevent auto-PEEP and air trapping, while managing non-uniform atelectasis with adequate baseline PEEP.
PPHN is characterized by suprasystemic pulmonary vascular resistance causing right-to-left shunting across the ductus arteriosus and foramen ovale, confirmed by a pre-to-post ductal SpO2 gradient >5-10% or PaO2 gradient >15-20 mmHg.
Transport management of PPHN centers on selective pulmonary vasodilation with inhaled nitric oxide (iNO starting at 20 ppm), avoiding agitation via deep sedation, and maintaining systemic blood pressure equal to or exceeding RV pressure with inotropic infusions.
Last updated: September 2026
Meconium Aspiration Syndrome (MAS) & Persistent Pulmonary Hypertension (PPHN)
Meconium Aspiration Syndrome (MAS) and Persistent Pulmonary Hypertension of the Newborn (PPHN) represent two of the most critical, high-risk respiratory emergencies encountered by neonatal transport teams. Often occurring in post-term, term, or growth-restricted infants following intrapartum asphyxia, these interrelated pathologies present an unforgiving physiological challenge. Transport clinicians must navigate complex ventilator-hemodynamic interactions: managing heterogeneous lung mechanics characterized by gas trapping and atelectasis while simultaneously blunting labile pulmonary vascular reactivity to reverse life-threatening extrapulmonary right-to-left shunting.
Pathophysiology of Meconium Aspiration Syndrome
Meconium passage occurs in 10% to 15% of all deliveries, most frequently in term and post-mature infants. Intrauterine stress—such as placental insufficiency, maternal preeclampsia, umbilical cord compression, or prolonged labor—triggers fetal hypoxia and acidosis. This physiological insult stimulates vagal outflow, relaxes the anal sphincter, increases gastrointestinal peristalsis, and causes meconium expulsion into the amniotic fluid. Concurrently, severe asphyxia triggers gasping inspiratory efforts in utero or during delivery, drawing particulate meconium deep into the tracheobronchial tree.
The Pathophysiological Triad of MAS
Once meconium enters the lower airways, it initiates three distinct and compounding mechanisms of lung injury:
Mechanical Airway Obstruction: Particulate meconium migrates into distal conducting airways. Complete obstruction causes distal gas absorption and non-uniform atelectasis. Partial obstruction generates a ball-valve effect : as the airway caliber expands during inspiration, air enters distal alveoli; during passive expiration, the airway narrows, trapping gas behind the meconium plug. This leads to severe dynamic hyperinflation, air trapping, and auto-PEEP . As alveolar overdistension escalates, terminal saccules rupture, producing air leak syndromes (pneumothorax or pneumomediastinum) in 20% to 30% of severe MAS cases.
Chemical Pneumonitis: Meconium contains bile salts, pancreatic proteolytic enzymes, free fatty acids, and bilirubin. Within hours of aspiration, these agents trigger an intense, sterile inflammatory reaction. Cytokines (TNF- α \alpha α , IL-1 β \beta β , IL-6) surge, damaging alveolar type I and type II epithelial cells, disrupting the capillary-alveolar barrier, and precipitating high-permeability, non-cardiogenic pulmonary edema.
Secondary Surfactant Inactivation: Free fatty acids in meconium directly displace dipalmitoylphosphatidylcholine from the alveolar surface and inhibit surfactant-associated proteins. This acute functional surfactant inactivation dramatically increases surface tension, producing diffuse atelectasis and compounding V/Q mismatch alongside hyperinflated zones. Intrauterine Asphyxia / Cord Compression / Post-Maturity
- │
- ▼
- Fetal Hypoxia ──► Vagal Tone ──► Meconium Passage & Deep In Utero Gasping
- │
- ▼
- Tracheobronchial Meconium Aspiration
- │
- ┌────┴───────────────────────────┬───────────────────────────┐
- ▼ ▼ ▼
- Mechanical Obstruction Chemical Pneumonitis Surfactant Inactivation
- Ball-valve mechanism • Bile salt inflammation • Fatty acid displacement
- Air trapping & auto-PEEP • Cytokine cascade • Alveolar collapse
- 20-30% Pneumothorax / PIE • Capillary leak edema • Severe V/Q mismatch
- └────┬───────────────────────────┴───────────────────────────┘
- │
- ▼
- Intractable Hypoxemia, Hypercapnia & Acidosis
- │
- ▼
- Persistent Pulmonary Hypertension of the Newborn (PPHN)
- (Suprasystemic PVR & Right-to-Left Shunt across PDA & PFO)
- Resuscitation & Suctioning Guidelines: The NRP Paradigm Shift
Historically, obstetricians routinely suctioned the meconium-stained infant's oropharynx on the perineum prior to delivery of the shoulders, and pediatricians immediately intubated all non-vigorous meconium-stained infants on the radiant warmer for deep tracheal suctioning.
The Contemporary Resuscitation Protocol
Extensive international clinical trials have definitively demonstrated that routine intrapartum suctioning and post-delivery tracheal intubation do not reduce the incidence of MAS, air leaks, or PPHN, nor do they improve survival. Crucially, attempting routine intubation in depressed infants causes significant harm by delaying positive pressure ventilation, aggravating hypoxia, and precipitating reflex vagal bradycardia and cardiac arrest.
According to current Neonatal Resuscitation Program (NRP) and international transport consensus standards:
No Routine Perineal or Tracheal Suctioning: Routine endotracheal intubation for suctioning is strictly abandoned for both vigorous and non-vigorous infants born through meconium-stained amniotic fluid.
Standard Resuscitation Sequence: The infant is brought immediately to the radiant warmer, positioned in a neutral 'sniffing' posture, dried, and stimulated.
Secretions Management: Clear secretions from the mouth and nose using a bulb syringe or wide-bore suction catheter (10–12 Fr, suction set at − 80 to − 100 mmHg -80\text{ to }-100\text{ mmHg} − 80 to − 100 mmHg ) only if the airway is obstructed or positive pressure ventilation is required.
The Golden Minute: If the infant remains apneic, gasping, or has a heart rate < 100 beats/min <100\text{ beats/min} < 100 beats/min , the resuscitation team must initiate positive pressure ventilation (PPV) immediately within the first 60 seconds of life.
Indications for Direct Tracheal Suctioning: Intubation and direct tracheal suctioning are reserved exclusively for infants with clear mechanical upper airway obstruction who fail to achieve chest rise and adequate heart rate response despite corrective ventilation steps (MR. SOPA).
Ventilator Management in MAS: Mitigating Auto-PEEP
Ventilating an infant with MAS is uniquely challenging because the lung pathology is fundamentally heterogeneous: stiff, collapsed atelectatic areas coexist adjacent to hyperinflated, fragile lung units.
Transport Ventilator Strategies
Longer Expiratory Time ( T e T_e T e ): In the presence of partial ball-valve obstructions, gas requires extended time to escape during exhalation. Clinicians must set lower ventilator rates ( 30 to 40 breaths/min ) and establish an inspiratory-to-expiratory ratio of I : E = 1 : 2 to 1 : 3 I:E = 1:2\text{ to }1:3 I : E = 1 : 2 to 1 : 3 , with an expiratory time T e ≥ 0.8 − 1.2 seconds T_e \ge 0.8 - 1.2\text{ seconds} T e ≥ 0.8 − 1.2 seconds . Short expiratory times prevent complete exhalation, leading to progressive dynamic hyperinflation, elevated auto-PEEP, decreased venous return, and tension pneumothorax.
PEEP Titration: Set baseline PEEP cautiously at 5.0 to 6.0 cmH2O . Inadequate PEEP promotes collapse of non-obstructed alveoli, while excessive PEEP ( > 7 cmH 2 O >7\text{ cmH}_2\text{O} > 7 cmH 2 O ) overdistends hyperinflated segments.
Permissive Hypercapnia: Allow PaCO 2 \text{PaCO}_2 PaCO 2 to rise to 45 to 60 mmHg (maintaining pH ≥ 7.25 \text{pH} \ge 7.25 pH ≥ 7.25 ) to avoid aggressive peak inspiratory pressures (keep PIP < 25 − 28 cmH 2 O \text{PIP} < 25-28\text{ cmH}_2\text{O} PIP < 25 − 28 cmH 2 O ). High PIP forces particulate meconium deeper into peripheral bronchioles and precipitates air leaks.
Surfactant Lavage / Replacement: In severe MAS with escalating oxygen requirements ( FiO 2 > 0.50 \text{FiO}_2 > 0.50 FiO 2 > 0.50 ), exogenous surfactant administration helps overcome meconium-induced surfactant inactivation, improves compliance, and reduces the need for extracorporeal membrane oxygenation (ECMO).
Persistent Pulmonary Hypertension of the Newborn (PPHN)
PPHN occurs when the normal circulatory transition at birth fails. In utero, pulmonary vascular resistance (PVR) is high, with only 10% to 15% of right ventricular output perfusing the lungs. At birth, lung expansion, alveolar oxygenation, and cord clamping normally trigger an abrupt 80% decrease in PVR, establishing low-pressure pulmonary circulation.
In PPHN, PVR remains elevated at or above systemic vascular resistance (SVR). Pathological mechanisms include:
Maladaptation: Structurally normal pulmonary vessels constricted by acute hypoxia, acidosis, hypothermia, or sepsis (frequently secondary to MAS, RDS, or GBS pneumonia).
Vascular Remodeling / Hypermuscularization: Smooth muscle hypertrophy extending into non-muscularized distal intra-acinar arterioles, typically caused by chronic intrauterine hypoxia or maternal NSAID/SSRI exposure.
Vascular Hypoplasia: Reduced cross-sectional area of the pulmonary arterial bed (e.g., Congenital Diaphragmatic Hernia, severe oligohydramnios).
Shunting Dynamics
When pulmonary artery pressure exceeds systemic arterial pressure, deoxygenated blood bypasses the pulmonary bed through persistent fetal channels:
Ductus Arteriosus: Right-to-left shunting from the main pulmonary artery into the descending aorta.
Foramen Ovale: Right-to-left shunting from the hypertensive right atrium into the left atrium.
This shunting results in severe, cyanotic, refractory arterial hypoxemia that is profoundly disproportionate to the parenchymal opacification seen on chest radiograph.
- Diagnostic Evaluation: Ductal Gradients, Hyperoxia & Echocardiography Ascending Aorta (Pre-Ductal Blood)
- ┌─────────────────────────────────┐
- │ Right Arm / Wrist (SpO2 #1) │
- └────────────────┬────────────────┘
- │
- Pulmonary Artery ──[Right-to-Left PDA Shunt]──► Descending Aorta (Post-Ductal Blood)
- │
- ▼
- Lower Extremities / Feet (SpO2 #2)
- Diagnostic Gradient: Pre-ductal SpO2 > Post-ductal SpO2 by >5-10% (or PaO2 by >15-20 mmHg)
- 1. Pre-Ductal vs. Post-Ductal Oxygenation Gradient
Sensor Placement: Place the pre-ductal pulse oximeter probe on the right hand or wrist . Blood supplying the right arm branches from the innominate (brachiocephalic) artery, originating proximal to the ductus arteriosus. Place the post-ductal probe on either foot (or left hand), receiving blood distal to the ductal insertion.
Diagnostic Threshold: A pre-ductal to post-ductal SpO 2 \text{SpO}_2 SpO 2 difference > 5 to 10 % > 5\text{ to }10\% > 5 to 10% or an arterial PaO 2 \text{PaO}_2 PaO 2 difference > 15 to 20 mmHg > 15\text{ to }20\text{ mmHg} > 15 to 20 mmHg confirms significant right-to-left shunting across a patent ductus arteriosus.
Diagnostic Pitfall (The PFO Trap): If right-to-left shunting occurs predominantly at the patent foramen ovale (PFO) , deoxygenated systemic venous blood mixes in the left atrium before entering the left ventricle. In this scenario, blood pumped into the ascending aorta is already desaturated; therefore, both pre-ductal and post-ductal saturations will be equally low , with no detectable gradient despite severe PPHN!
2. The Hyperoxia Test
Administer 100% FiO 2 \text{FiO}_2 FiO 2 for 10 to 15 minutes. In pure parenchymal lung disease, alveolar recruitment typically raises arterial PaO 2 > 150 − 200 mmHg \text{PaO}_2 > 150-200\text{ mmHg} PaO 2 > 150 − 200 mmHg . In PPHN or cyanotic congenital heart disease (such as Transposition of the Great Arteries), PaO 2 \text{PaO}_2 PaO 2 typically fails to rise above 100 to 150 mmHg 100\text{ to }150\text{ mmHg} 100 to 150 mmHg due to fixed anatomical or physiological right-to-left shunts.
3. Bedside Echocardiography
Echocardiography is the gold standard diagnostic modality. Key findings include:
Septal Flattening: The interventricular septum flattens or bows into the left ventricle during systole (producing a classic 'D-shaped' LV on parasternal short-axis view), reflecting right ventricular pressure overload.
Tricuspid Regurgitation (TR) Jet: Doppler measurement of peak TR jet velocity calculates estimated RV systolic pressure using the modified Bernoulli equation ( Δ P = 4 v 2 + RAP \Delta P = 4v^2 + \text{RAP} Δ P = 4 v 2 + RAP ).
Directional Shunting: Direct Doppler visualization of right-to-left or bidirectional flow across the PDA and PFO.
Loading diagram... PPHN Transport Stabilization & Right-to-Left Shunt Reversal
Transport Management: Inhaled Nitric Oxide, Hemodynamics & Sedation
Transporting an infant with severe PPHN demands rigorous stabilization prior to departure. The primary therapeutic goal is to lower pulmonary vascular resistance below systemic vascular resistance , thereby reversing right-to-left shunting.
1. Inhaled Nitric Oxide (iNO) Protocols
Inhaled Nitric Oxide is a selective pulmonary vasodilator. As a lipophilic gas, it diffuses across alveolar membranes into adjacent vascular smooth muscle, activating soluble guanylyl cyclase to convert GTP to cyclic guanosine monophosphate (cGMP). Elevated cGMP drives calcium extrusion, causing smooth muscle relaxation.
Absence of Systemic Hypotension: Upon entering the pulmonary capillary bed, nitric oxide binds hemoglobin with extremely high affinity, rapidly forming nitrosyl-hemoglobin and methemoglobin. This completely inactivates the drug, preventing systemic vasodilation or hypotension.
Dosing: Initiate iNO at 20 ppm . Clinical trials confirm that doses > 20 ppm >20\text{ ppm} > 20 ppm do not confer additional vasodilation and significantly increase the risk of methemoglobinemia and nitrogen dioxide toxicity.
Transport Monitoring: Monitor methemoglobin levels via co-oximetry (keep < 2.5 − 3.0 % <2.5-3.0\% < 2.5 − 3.0% ) and nitrogen dioxide ( NO 2 \text{NO}_2 NO 2 ) levels (keep < 1.0 − 2.0 ppm <1.0-2.0\text{ ppm} < 1.0 − 2.0 ppm ). Transport crews must utilize certified portable delivery systems (e.g., AeroNOx, INOmax DSIR) equipped with dedicated gas scavenging and backup cylinders.
CRITICAL TRANSPORT WARNING: Rebound PPHN
Inhaled nitric oxide suppresses endogenous nitric oxide synthase (eNOS) activity. Abrupt discontinuation of iNO—such as running out of gas in flight, circuit disconnection, or equipment failure—triggers immediate, severe rebound pulmonary vasoconstriction .
Pulmonary vascular resistance skyrockets above systemic pressure within 30 to 60 seconds, precipitating acute right ventricular failure, profound desaturation ( SpO 2 < 50 % \text{SpO}_2 < 50\% SpO 2 < 50% ), severe bradycardia, and death.
Transport Rule: Never abruptly discontinue or interrupt iNO therapy during transit. Transport teams must carry dual pressurized cylinders and verify tank volumes prior to departure.
2. Hemodynamic Support & Blood Pressure Targets
Right-to-left shunting across the ductus arteriosus depends directly on the balance between pulmonary and systemic pressure. If systemic mean arterial pressure (MAP) falls below pulmonary artery pressure, right-to-left shunting intensifies.
Target: Maintain systemic MAP at or slightly above expected normal limits (typically MAP ≥ 45 − 55 mmHg \text{MAP} \ge 45-55\text{ mmHg} MAP ≥ 45 − 55 mmHg in term neonates) to equalize or exceed RV pressure.
Vasoactive Infusions:
Epinephrine (0.05 to 0.2 mcg/kg/min): First-line inotropic and vasopressor agent. Enhances myocardial contractility and elevates SVR.
Norepinephrine (0.05 to 0.3 mcg/kg/min): Potent α 1 \alpha_1 α 1 -adrenergic agonist; restores systemic vascular tone in vasodilatory states.
Milrinone (0.25 to 0.5 mcg/kg/min): A phosphodiesterase-3 inhibitor that reduces both PVR and SVR while augmenting RV contractility and lusitropy. Transport Rule: Always omit the hospital loading bolus to prevent catastrophic systemic hypotension, and ensure systemic blood pressure is maintained with concurrent vasopressors if needed.
3. Sedation, Analgesia & Neuromuscular Blockade
The pulmonary vascular bed in term neonates is exquisitely sensitive to catecholamine surges, agitation, cold stress, and tactile stimulation (such as tracheal suctioning). Crying triggers acute pulmonary hypertensive crises.
Administer continuous analgesia with fentanyl (1 to 3 mcg/kg/hr) .
Initiate neuromuscular blockade with rocuronium (1.0 mg/kg) or vecuronium (0.1 mg/kg) if the infant exhibits ventilator dyssynchrony or agitation that destabilizes oxygenation.
4. Ventilation & Acid-Base Targets
Acid-Base Targets: Target normal to mild alkalosis ( pH 7.35 to 7.45 \text{pH } 7.35\text{ to }7.45 pH 7.35 to 7.45 , PaCO 2 35 to 45 mmHg \text{PaCO}_2 35\text{ to }45\text{ mmHg} PaCO 2 35 to 45 mmHg ).
The Abandonment of Hyperventilation: Historically, clinicians induced extreme hyperventilation and sodium bicarbonate infusions to achieve profound alkalosis ( pH > 7.55 \text{pH} > 7.55 pH > 7.55 , PaCO 2 < 25 mmHg \text{PaCO}_2 < 25\text{ mmHg} PaCO 2 < 25 mmHg ). This practice is strictly contraindicated : severe hypocarbic alkalosis produces intense cerebral vasoconstriction, causing permanent ischemic brain injury, periventricular leukomalacia, and sensorineural hearing loss.
Oxygenation Targets: Maintain pre-ductal SpO 2 \text{SpO}_2 SpO 2 at 92% to 97% and PaO 2 \text{PaO}_2 PaO 2 between 60 and 90 mmHg .